China Universal Asset Management Co. Ltd. lifted its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 419.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 46,202 shares of the company's stock after purchasing an additional 37,311 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in Genmab A/S were worth $905,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its stake in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after buying an additional 939 shares during the last quarter. Barclays PLC grew its stake in Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Genmab A/S in the 4th quarter valued at about $60,000. Aquatic Capital Management LLC acquired a new position in Genmab A/S in the 4th quarter valued at about $114,000. Finally, Blue Trust Inc. grew its stake in Genmab A/S by 169.9% in the 1st quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock valued at $145,000 after buying an additional 4,666 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.
Genmab A/S Price Performance
GMAB stock opened at $21.25 on Wednesday. The company has a 50 day simple moving average of $21.01 and a 200 day simple moving average of $20.73. The stock has a market cap of $13.63 billion, a price-to-earnings ratio of 12.07, a P/E/G ratio of 6.69 and a beta of 0.94. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $28.56.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. The business had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. On average, equities research analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.
Analyst Ratings Changes
A number of analysts have issued reports on GMAB shares. Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Wall Street Zen downgraded shares of Genmab A/S from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. HC Wainwright reissued a "buy" rating and issued a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Finally, Truist Financial boosted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $37.80.
Check Out Our Latest Stock Report on Genmab A/S
About Genmab A/S
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
